Frontlight ResearchEarly access
CompletedNo phase
Assessment of Biomarkers in Children to Help Parents Quit Tobacco
Key facts
- Who runs it
- Massachusetts General Hospital
- Where
- Cleveland, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 865 people enrolled
- Started
- 20 Jan 2023
- Ended
- 1 May 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- CEASE
- CEASE + BIO
- Record updated
- 15 June 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Child 12 years old or younger presenting for a visit
- Child scheduled for or has had a clinically indicated blood draw at that visit
- Parent/legal guardian of the child
- Parent/legal guardian is a current smoker (past 7 days)
Who cannot take part
- Parent/legal guardian is less than 18 years of age
- Parent/legal guardian is non-English speaking
Where in United States
- MetroHealth SystemCleveland, United States
About the trial
What the trial wants to find out
This randomized controlled trial will test whether adding biomarker measurement and informed outreach for tobacco smoke exposure as part of routine practice increases identification and improves treatment, effectiveness, and sustainability of a parental tobacco control intervention that will be integrated into pediatric practice.
The 2 groups in the trial
- CEASEExisting treatment, for comparison
Those assigned to the Active Comparator arm will receive the CEASE intervention.
- CEASE + BIOTreatment being tested
Those assigned to the Experimental CEASE + BIO arm will receive the CEASE intervention plus Biomarker Informed Outreach (BIO).
Treatment: CEASE and CEASE + BIO
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 15 June 2026